WO2014020546A2 - Formes cristallines d'étexilate de dabigatran et leur procédé de préparation - Google Patents

Formes cristallines d'étexilate de dabigatran et leur procédé de préparation Download PDF

Info

Publication number
WO2014020546A2
WO2014020546A2 PCT/IB2013/056266 IB2013056266W WO2014020546A2 WO 2014020546 A2 WO2014020546 A2 WO 2014020546A2 IB 2013056266 W IB2013056266 W IB 2013056266W WO 2014020546 A2 WO2014020546 A2 WO 2014020546A2
Authority
WO
WIPO (PCT)
Prior art keywords
dabigatran etexilate
crystalline form
xrpd pattern
dabigatran
values
Prior art date
Application number
PCT/IB2013/056266
Other languages
English (en)
Other versions
WO2014020546A3 (fr
Inventor
Balaguru Murugesan
Sudhir Singh Sanwal
Anandam VEMAPLI
Swargam Sathyanarayana
Rajesh Kumar Thaper
Mohan Prasad
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2014020546A2 publication Critical patent/WO2014020546A2/fr
Publication of WO2014020546A3 publication Critical patent/WO2014020546A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates to crystalline Form 1 , Form 2, Form 3, and Form 4 of dabigatran etexilate and processes for their preparation.
  • the present invention further relates to processes for the preparation of a dabigatran etexilate methanesulfonate salt using crystalline Form 1 , Form 2, Form 3, and Form 4 of dabigatran etexilate.
  • PRADAXA ® is the methanesulfonate salt of dabigatran etexilate, which is chemically described as ⁇ -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl] amino]methyl]-l -methyl- lH-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate salt of Formula I.
  • FORMULA II is a prodrug of dabigatran of Formula III
  • Dabigatran etexilate is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It may be used alone or in combination with other therapeutic agents.
  • the present invention relates to crystalline Form 1, Form 2, Form 3, and Form 4 of dabigatran etexilate and processes for their preparation.
  • the present invention further relates to processes for the preparation of dabigatran etexilate methanesulfonate salt using crystalline Form 1, Form 2, Form 3, and Form 4 of dabigatran etexilate.
  • Figure 1 depicts the X-ray powder diffraction (XRPD) pattern of crystalline Form 1 of dabigatran etexilate obtained according to Example 1.
  • Figure 1A provides the table of values for the XRPD pattern depicted in Figure 1.
  • Figure 2 depicts the XRPD pattern of crystalline Form 2 of dabigatran etexilate obtained according to Example 2.
  • Figure 2A provides the table of values for the XRPD pattern depicted in Figure 2.
  • Figure 3 depicts the XRPD pattern of crystalline Form 3 of dabigatran etexilate obtained according to Example 3.
  • Figure 3 A provides the table of values for the XRPD pattern depicted in Figure 3.
  • Figure 4 depicts the XRPD pattern of crystalline Form 4 of dabigatran etexilate obtained according to Example 4.
  • Figure 4A provides the table of values for the XRPD pattern depicted in Figure 4.
  • Figure 5 depicts the Differential Scanning Calorimetry (DSC) thermogram of crystalline Form 1 of dabigatran etexilate obtained according to Example 1.
  • Figure 6 depicts the DSC thermogram of crystalline Form 2 of dabigatran etexilate obtained according to Example 2.
  • Figure 7 depicts the DSC thermogram of crystalline Form 3 of dabigatran etexilate obtained according to Example 3.
  • a first aspect of the present invention provides crystalline Form 1 of dabigatran etexilate.
  • the crystalline Form 1 of dabigatran etexilate has substantially the same XRPD (X-ray powder diffraction) pattern as depicted in Figure 1.
  • the crystalline Form 1 of dabigatran etexilate is characterized by an XRPD pattern having interplanar spacing (d) values substantially at 5.74, 4.42, 4.00, 3.68, 3.63, and 3.48 A.
  • the crystalline Form 1 of dabigatran etexilate is further characterized by an XRPD pattern having interplanar spacing (d) values at about 20.03, 18.28, 10.62, 10.06, 8.53, 7.68, 6.69, 6.44, 6.04, 5.74, 5.34, 5.23, 4.94, 4.42, 4.28, 4.13, 4.00, 3.92, 3.82, 3.68, 3.63, 3.48, 3.35, 3.25, 3.16, 3.1 1, 3.03, 2.87, 2.78, 2.72, 2.65, 2.59, 2.46, and 2.32 A.
  • d interplanar spacing
  • the crystalline Form 1 of dabigatran etexilate may further be characterized by a differential scanning calorimetry (DSC) thermogram substantially the same as that depicted in Figure 5.
  • the crystalline Form 1 of dabigatran etexilate has characteristic DSC endothermic peaks at about 51.42°C, 73.42°C, 99.62°C, 108.41°C, 121.91°C, and 131.52°C.
  • a second aspect of the present invention provides crystalline Form 2 of dabigatran etexilate.
  • the crystalline Form 2 of dabigatran etexilate has substantially the same XRPD pattern as depicted in Figure 2.
  • the crystalline Form 2 of dabigatran etexilate is characterized by an XRPD pattern having interplanar spacing (d) values at about 14.95, 7.48, 4.96, 4.49, 4.27, 4.16, 3.57, and 3.40 A.
  • the crystalline Form 2 of dabigatran etexilate is further characterized by an XRPD pattern having interplanar spacing (d) values at about 14.95, 13.43, 10.69, 8.04, 7.48, 7.28, 6.74, 6.45, 5.92, 5.75, 4.96, 4.49, 4.40, 4.27, 4.16, 3.84, 3.67, 3.57, 3.40, 3.32, 3.16, 2.73, and 2.49 A.
  • the crystalline Form 2 of dabigatran etexilate may further be characterized by a differential scanning calorimetry (DSC) thermogram substantially the same as that depicted in Figure 6.
  • the crystalline Form 2 of dabigatran etexilate has a characteristic DSC endothermic peak at about 77.61°C.
  • a third aspect of the present invention provides crystalline Form 3 of dabigatran etexilate.
  • the crystalline Form 3 of dabigatran etexilate has substantially the same XRPD pattern as depicted in Figure 3.
  • the crystalline Form 3 of dabigatran etexilate is characterized by an XRPD pattern having interplanar spacing (d) values at about 6.57,
  • the crystalline Form 3 of dabigatran etexilate is further characterized by an XRPD pattern having interplanar spacing (d) values at about 27.77,
  • the crystalline Form 3 of dabigatran etexilate may further be characterized by a differential scanning calorimetry (DSC) thermogram substantially the same as depicted in Figure 7.
  • the crystalline Form 3 of dabigatran etexilate has characteristic DSC endothermic peaks at about 53.67°C, 75.66°C, 106.58°C, 122.12°C, and 131.22°C.
  • a fourth aspect of the present invention provides crystalline Form 4 of dabigatran etexilate.
  • the crystalline Form 4 of dabigatran etexilate has substantially the same XRPD pattern as depicted in Figure 4.
  • the crystalline Form 4 of dabigatran etexilate is characterized by an XRPD pattern having interplanar spacing (d) values at about 10.00, 5.71, 5.33, 4.41, 3.68, and 3.62 A.
  • the crystalline Form 4 of dabigatran etexilate is further characterized by an XRPD pattern having interplanar spacing (d) values at about 18.05, 10.45, 10.00, 8.53, 7.61, 6.70, 6.50, 6.34, 6.03, 5.71, 5.33, 5.09, 4.88, 4.41, 4.27, 4.13, 4.01, 3.91 , 3.81, 3.68, 3.62, 3.54, 3.48, 3.34, 3.25, 3.17, 3.12, 3.02, 2.85, 2.78, 2.72, 2.66, 2.58, 2.46, and 2.32 A.
  • a fifth aspect of the present invention provides a process for the preparation of crystalline Form 1 of dabigatran etexilate wherein the process comprises:
  • Dabigatran etexilate existing in any solid or non-solid form known in the prior art may be used as the starting material.
  • Dabigatran etexilate may be prepared, for example, according to the methods disclosed in U.S. Patent No. 6,087,380.
  • Dabigatran etexilate is treated with hexanol.
  • the treatment with hexanol may be carried out at a temperature of about 10°C to about 100°C, for example, about 20°C to about 80°C.
  • the treatment with hexanol may be carried out for about 2 hours to about 7 hours, for example, about 4 hours to about 5 hours.
  • the hexanol may be used alone or in combination with an organic solvent.
  • the treatment with hexanol is optionally preceded or followed by treatment with an organic solvent.
  • the organic solvent may be selected from the group comprising of alcohols, esters, nitriles, or mixtures thereof.
  • the alcohol may be, for example, ethanol, methanol, 2-propanol, or butanol.
  • the ester may be, for example, methyl acetate, ethyl acetate, or butyl acetate.
  • the nitrile may be, for example, acetonitrile.
  • the reaction mixture is stirred for about 1 hour to about 5 hours, for example, about 2 hours to about 3 hours.
  • the crystalline Form 1 of dabigatran etexilate may be isolated from the reaction mixture by filtration, cooling, evaporation, decantation, distillation, vacuum drying, or combinations thereof.
  • a sixth aspect of the present invention provides a process for the preparation of crystalline Form 2 of dabigatran etexilate, wherein the process comprises:
  • Dabigatran etexilate existing in any solid or non-solid form known in the prior art may be used as the starting material.
  • Dabigatran etexilate may be prepared, for example, according to the methods disclosed in U.S. Patent No. 6,087,380.
  • Dabigatran etexilate is treated with t-butanol at a temperature of about 10°C to about 100°C, for example, about 20°C to about 80°C.
  • the treatment with t-butanol may be carried out for about 2 hours to about 7 hours, for example about 4 hours to about 5 hours.
  • the t-butanol may be used alone, or in combination with an organic solvent.
  • the treatment with t-butanol is optionally preceded or followed by treatment with an organic solvent.
  • the organic solvent may be selected from the group comprising of alcohols, esters, nitriles, or mixtures thereof.
  • the alcohol may be, for example, ethanol, methanol, 2-propanol, or butanol.
  • the ester may be, for example, methyl acetate, ethyl acetate, or butyl acetate.
  • the nitrile may be, for example, acetonitrile.
  • the reaction mixture is stirred for about 1 hour to about 5 hours, for example, about 2 hours to about 3 hours.
  • the crystalline Form 2 of dabigatran etexilate may be isolated from the reaction mixture by filtration, cooling, evaporation, decantation, distillation, vacuum drying, or combinations thereof.
  • a seventh aspect of the present invention provides a process for the preparation of crystalline Form 3 of dabigatran etexilate wherein the process comprises:
  • Dabigatran etexilate existing in any solid or non-solid form known in the prior art may be used as the starting material.
  • Dabigatran etexilate may be prepared, for example, according to the methods disclosed in U.S. Patent No. 6,087,380.
  • Dabigatran etexilate is treated with toluene at a temperature of about 10°C to about 100°C, for example, about 20°C to about 80°C, for about 2 hours to about 7 hours, for example, about 4 hours to about 5 hours.
  • the toluene may be used alone, or in combination with an organic solvent.
  • the treatment with toluene is optionally preceded or followed by treatment with an organic solvent.
  • the organic solvent may be selected from the group comprising of alcohols, esters, nitriles, or mixtures thereof.
  • the alcohol may be, for example, ethanol, methanol, 2-propanol, or butanol.
  • the ester may be, for example, methyl acetate, ethyl acetate, or butyl acetate.
  • the nitrile may be, for example, acetonitrile.
  • the reaction mixture is stirred for about 1 hour to about 5 hours, for example, about 2 hours to about 3 hours.
  • the crystalline Form 3 of dabigatran etexilate may be isolated from the reaction mixture by filtration, cooling, evaporation, decantation, distillation, vacuum drying, or combinations thereof.
  • An eighth aspect of the present invention provides a process for the preparation of crystalline Form 4 of dabigatran etexilate wherein the process comprises:
  • Dabigatran etexilate existing in any solid or non-solid form known in the prior art may be used as the starting material.
  • Dabigatran etexilate may be prepared, for example, according to the methods disclosed in U.S. Patent No. 6,087,380.
  • Dabigatran etexilate is treated with methyl acetate.
  • the treatment with methyl acetate may be carried out at a temperature of about 10°C to about 100°C, for example, about 20°C to about 80°C.
  • the treatment with methyl acetate may be carried out for about 2 hours to about 7 hours, for example, about 4 hours to about 5 hours.
  • the methyl acetate may be used alone or in combination with an organic solvent.
  • the treatment with methyl acetate is optionally preceded or followed by treatment with an organic solvent.
  • the organic solvent may be selected from the group comprising of alcohols, esters, nitriles, or mixtures thereof.
  • the alcohol may be, for example, ethanol, methanol, 2-propanol, or butanol.
  • the ester may be, for example, ethyl acetate, or butyl acetate.
  • the nitrile may be, for example, acetonitrile.
  • the reaction mixture is stirred for about 1 hour to about 5 hours, for example, about 2 hours to about 3 hours.
  • the crystalline Form 4 of dabigatran etexilate may be isolated from the reaction mixture by filtration, cooling, evaporation, decantation, distillation, vacuum drying, or combinations thereof.
  • a ninth aspect of the present invention provides a process for the preparation of dabigatran etexilate methanesulfonate salt wherein the process comprises:
  • a tenth aspect of the present invention provides a pharmaceutical composition comprising crystalline Form 1, Form 2, Form 3, or Form 4 of dabigatran etexilate, or any combination of said forms, and a pharmaceutically acceptable excipient.
  • An eleventh aspect of the present invention provides a method of treating or preventing blood clots in a patient suffering from or susceptible to the formation of blood clots, comprising administering a pharmaceutical composition comprising crystalline Form 1, Form 2, Form 3, or Form 4 of dabigatran etexilate, or any combination of said forms.
  • Dabigatran etexilate (2 g) was added to hexanol (25 mL) at 25°C to 30°C.
  • the temperature of the reaction mixture was increased to 70°C to 75°C, and the mixture was stirred for 5 minutes to 10 minutes.
  • the reaction mixture was cooled to 20°C to 25°C and stirred for 2 hours to 3 hours.
  • the solid obtained was filtered under vacuum, and washed with hexanol (10 mL). The solid obtained was suck dried, and further dried under vacuum at 50°C to 55°C for 15 hours to give the title compound having an XRPD pattern as shown in Figure 1.
  • Dabigatran etexilate (2 g) was added to t-butanol (25 mL) at 25°C to 30°C.
  • the temperature of the reaction mixture was increased to 70°C to 75°C, and it was stirred for 5 minutes to 10 minutes.
  • the reaction mixture was cooled to 20°C to 25°C and stirred for 2 hours to 3 hours.
  • the solid obtained was filtered under vacuum and washed with t-butanol (10 mL). The solid obtained was suck dried, and further dried under vacuum at 50°C to 55°C for 15 hours to give the title compound having an XRPD pattern as shown in Figure 2.
  • Dabigatran etexilate (2 g) was added to toluene (25 mL) at 25°C to 30°C.
  • the temperature of the reaction mixture was increased to 70°C to 75°C, and it was stirred for 5 minutes to 10 minutes.
  • the reaction mixture was cooled to 20°C to 25°C and stirred for 2 hours to 3 hours.
  • the solid obtained was filtered under vacuum and washed with toluene (10 mL). The solid obtained was suck dried, and further dried under vacuum at 50°C to 55°C for 15 hours to give the title compound having an XRPD pattern as shown in Figure 3.
  • Dabigatran etexilate (2 g) was added to methyl acetate (25 mL) at 25°C to 30°C.
  • the temperature of the reaction mixture was increased to 70°C to 75°C, and it was stirred for 5 minutes to 10 minutes.
  • the reaction mixture was cooled to 20°C to 25°C, and stirred for 2 hours to 3 hours.
  • the solid obtained was filtered under vacuum and washed with methyl acetate (10 mL). The solid obtained was suck dried, and further dried under vacuum at 50°C to 55°C for 15 hours to give the title compound having XRPD as shown in Figure 4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne la Forme 1, Forme 2, Forme 3, et Forme 4 cristallines de l'étexilate de dabigatran, et des procédés pour les préparer. Cette invention concerne en outre des procédés de préparation d'un sel d'étexilate-méthanesulfonate de dabigatran faisant appel auxdites Forme 1, Forme 2, Forme 3, et Forme 4 cristallines de l'étexilate de dabigatran.
PCT/IB2013/056266 2012-07-31 2013-07-30 Formes cristallines d'étexilate de dabigatran et leur procédé de préparation WO2014020546A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2373DE2012 2012-07-31
IN2373/DEL/2012 2012-07-31

Publications (2)

Publication Number Publication Date
WO2014020546A2 true WO2014020546A2 (fr) 2014-02-06
WO2014020546A3 WO2014020546A3 (fr) 2014-03-27

Family

ID=49328583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/056266 WO2014020546A2 (fr) 2012-07-31 2013-07-30 Formes cristallines d'étexilate de dabigatran et leur procédé de préparation

Country Status (1)

Country Link
WO (1) WO2014020546A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174090A1 (fr) * 2022-03-15 2023-09-21 青岛华麒医药科技创新发展有限公司 Cocristal d'étexilate de dabigatran et son procédé de préparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US20060183779A1 (en) 2002-03-07 2006-08-17 Boehringer Ingelheim Pharma Gmbh & Co., Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20060276513A1 (en) 2005-06-04 2006-12-07 Boehringer Ingelheim International Gmbh Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
WO2008059029A2 (fr) 2006-11-16 2008-05-22 Boehringer Ingelheim International Gmbh Nouveaux polymorphes d'éthyle 3-[(2-{[4- (hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate
WO2011110478A1 (fr) 2010-03-08 2011-09-15 Ratiopharm Gmbh Composition pharmaceutique contenant du dabigatran étexilate
WO2012027543A1 (fr) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2610251A1 (fr) * 2011-12-29 2013-07-03 Zaklady Farmaceutyczne Polpharma SA Nouvelles formes polymorphes de dabigatran etexilate et leur procédé de préparation
WO2013124749A1 (fr) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Nouveau polymorphe d'étéxilate de dabigatran

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US20060183779A1 (en) 2002-03-07 2006-08-17 Boehringer Ingelheim Pharma Gmbh & Co., Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20060276513A1 (en) 2005-06-04 2006-12-07 Boehringer Ingelheim International Gmbh Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
WO2008059029A2 (fr) 2006-11-16 2008-05-22 Boehringer Ingelheim International Gmbh Nouveaux polymorphes d'éthyle 3-[(2-{[4- (hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate
WO2011110478A1 (fr) 2010-03-08 2011-09-15 Ratiopharm Gmbh Composition pharmaceutique contenant du dabigatran étexilate
WO2012027543A1 (fr) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174090A1 (fr) * 2022-03-15 2023-09-21 青岛华麒医药科技创新发展有限公司 Cocristal d'étexilate de dabigatran et son procédé de préparation

Also Published As

Publication number Publication date
WO2014020546A3 (fr) 2014-03-27

Similar Documents

Publication Publication Date Title
KR102435676B1 (ko) 독성 알데히드 관련된 질병 및 치료
CA2747427C (fr) Methode de production d'un derive de diamine
JP2012528877A (ja) ピルフェニドンを合成するための改善された方法
TW201441186A (zh) 用於治療纖維化之經取代之芳族化合物及相關方法
CN101885684B (zh) 带有一氧化氮供体的芳香酸前体药物及其制备方法和其应用
EP3693358B1 (fr) Composé hétéroaryle contenant de l'azote, et son utilisation pharmaceutique
KR102598775B1 (ko) Ｒｏｒ­감마 조절제
KR101539588B1 (ko) (6，7-디히드로-2-니트로-5ｈ-이미다졸[2,1-ｂ][1,3]옥사진-6-일)아미드 화합물, 그의 제조방법 및 용도
BG62090B1 (bg) Заместени бензамидини, тяхното получаване и използването имкато лекарствени средства
KR102572626B1 (ko) 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법
WO2017134615A1 (fr) Formes solides de dasatinib et leurs procédés de préparation
EP2631234A1 (fr) Formes solides de mesylate d'étexilate de dabigatran et leurs procédés de préparation
AU2010294277B2 (en) 5- (3, 4-dichloro-phenyl) -N- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as HDL cholesterol raising agents
CA2885994A1 (fr) Procede de preparation d'etexilate de dabigatran ou d'un sel pharmaceutiquement acceptable de cette substance
US20100280077A1 (en) Process for Preparation of Stable Amorphous R-Lansoprazole
WO2014020546A2 (fr) Formes cristallines d'étexilate de dabigatran et leur procédé de préparation
US20150225370A1 (en) Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
CN108349872A (zh) 三联苯化合物的合成
EP2714683A2 (fr) Ritonavir amorphe co-précipité
US11117860B2 (en) Phenyl urea derivatives as n-formyl peptide receptor modulators
JP2017505788A (ja) イオンチャネルモジュレーターの固体形態
US9150542B2 (en) Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate
US20150080420A1 (en) Amorphous form of lopinavir and ritonavir mixture
WO2011158262A1 (fr) Forme polymorphe du chlorhydrate de fexofénadine, intermédiaires et procédé de préparation
WO2014147641A2 (fr) Sel de phosphate de sitagliptine et de ptérostilbène, son procédé de préparation et composition pharmaceutique en contenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13774806

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13774806

Country of ref document: EP

Kind code of ref document: A2